LEARN MORE ABOUT DR. BILAL BIN HAFEEZ

Community NewsNews
1386

Translate to Spanish or other 102 languages!

Graduate research assistants Emmanuel Anning, Godwin Peasah-Darkwah and Asif Shahriar work in the lab to assist in the development of a treatment for advanced pancreatic cancer. (UTRGV Image Office of Research & New Program Development)

Mega Doctor News

- Advertisement -

Hafeez is the founding member of the first nationally recognized South Texas Center of Excellence in Cancer Immunology at the UTRGV School of Medicine and is an accomplished researcher with a background in immunopharmacology, cancer therapeutics and cancer biology. Hafeez, a Nehtaur, Bijnor, Uttar Pradesh, India native, has earned prestigious grant awards and is an active member of the American Association for Cancer Research and the Indian Association for Cancer Research. His significant contributions to cancer biology and molecular therapeutics have led to his numerous published manuscripts in scientific journals. 

- Advertisement -
- Advertisement -

Latest news

- Advertisement -
Previous article
School of Medicine earns $1.45M grant for pancreatic cancer research
Next article
Nursing and Allied Health to host new conference dedicated to health careers for students

More Articles

Study: Supplement Plus Chemo Boosts Pancreatic Cancer Survival

L-glutamine, an amino acid that occurs naturally in the body and plays an important role in digestion, has been studied as a potential way to ease side effects in other cancers.

How Artificial Intelligence Is Improving Prostate Cancer Diagnostics

Mega Doctor News CLEVELAND CLINIC - September is Prostate Cancer Awareness Month.  Prostate cancer is...

FDA Approves First Drug of Its Kind for Polycythemia Vera, a Rare Blood Disorder

The U.S. Food and Drug Administration today approved Mimrylo (rusfertide), a new treatment for adults with polycythemia vera, a rare blood disorder that causes the body to make too many red blood cells.

FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults

Lisraya is the first FDA-approved oral treatment option for patients with dermatomyositis, addressing the high unmet need for this rare disease.
- Advertisement -